2005
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
D’Souza D, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57: 594-608. PMID: 15780846, DOI: 10.1016/j.biopsych.2004.12.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAkathisia, Drug-InducedArousalCognitionDose-Response Relationship, DrugDouble-Blind MethodDronabinolEndocrine SystemFemaleHumansInjections, IntravenousMaleMental RecallMiddle AgedMotor ActivityNeuropsychological TestsPerceptionPsychiatric Status Rating ScalesPsychotic DisordersPsychotropic DrugsSchizophreniaVerbal LearningConceptsSchizophrenia patientsAntipsychotic-treated schizophrenia patientsDelta-9-tetrahydrocannabinol effectsLong-term adverse eventsCognitive deficitsPlacebo-controlled studyDelta-9-THCTransient exacerbationAdverse eventsReceptor dysfunctionEndocrine effectsHealthy subjectsStudy participationPsychotic disordersPlasma prolactinSchizophrenia symptomsPatientsSchizophreniaCognitive effectsPerceptual alterationsDeficitsCannabisSubjectsAkathisiaExacerbation
2002
Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms
Abi-Saab W, Seibyl JP, D'Souza C, Karper LP, Gueorgueva R, Abi-Dargham A, Wong ML, Rajhans S, Erdos JP, Heninger GR, Charney DS, Krystal JH. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology 2002, 162: 55-62. PMID: 12107618, DOI: 10.1007/s00213-002-1057-7.Peer-Reviewed Original ResearchConceptsReceptor antagonismSchizophrenic patientsNeuroleptic-free schizophrenic patientsBrief Psychiatric Rating ScaleDouble-blind conditionsPsychiatric Rating ScaleTest dayRitanserin pretreatmentIntravenous infusionReceptor modulationAntipsychotic activityMale inpatientsReceptor stimulationPlasma prolactinCortisol levelsSchizoaffective disorderSchizophrenia symptomsPositive symptomsNegative symptomsRandomized orderPatientsRating ScaleBehavioral activationSymptomsRitanserin
1999
Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors?
Whale R, Bhagwagar Z, Cowen P. Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors? Psychopharmacology 1999, 145: 223-226. PMID: 10463324, DOI: 10.1007/s002130051052.Peer-Reviewed Original ResearchConceptsPlasma growth hormoneGrowth hormoneCross-over design studyEffect of ketanserinGrowth hormone responsePathophysiology of depressionGrowth hormone releaseNeuroendocrine probeAntidepressant medicationHealthy menReceptor agonistReceptor subtypesHormone releaseHealthy volunteersBlood samplesNeuroendocrine profilePlasma prolactinAgonist activityHormone responseReceptor functionAssay of prolactinZolmitriptanHormoneOral temperatureMode of action
1994
Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms
Krystal JH, Webb E, Cooney N, Kranzler HR, Charney DS. Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms. JAMA Psychiatry 1994, 51: 898-911. PMID: 7944878, DOI: 10.1001/archpsyc.1994.03950110058008.Peer-Reviewed Original ResearchConceptsVisual analog scaleAnalog scaleScale scoreVisual analog scale scoreYohimbine hydrochlorideAnalog scale scoreDouble-blind conditionsEffect of mCPPReceptor partial agonistEffects of ethanolNoradrenergic mechanismsIntravenous infusionPlasma levelsSerotonergic systemNoradrenergic systemPlaceboDiscriminative propertiesMale inpatientsYohimbinePlasma prolactinCortisol levelsPartial agonistSerotonergic contributionAlcohol dependenceDays of testing
1989
Neurochemical Study of Dopamine Functioning in Autistic and Normal Subjects
MINDERAA R, ANDERSON G, VOLKMAR F, AKKERHUIS G, COHEN D. Neurochemical Study of Dopamine Functioning in Autistic and Normal Subjects. Journal Of The American Academy Of Child & Adolescent Psychiatry 1989, 28: 190-194. PMID: 2925571, DOI: 10.1097/00004583-198903000-00007.Peer-Reviewed Original ResearchConceptsPlasma PRLPlasma prolactinHVA levelsUrinary HVANormal controlsNormal subjectsUrinary DA excretionUrinary HVA excretionHomovanillic acid levelsDose of neurolepticPlasma PRL valuesDopamine functioningDopamine excretionNeuroleptic doseHVA excretionNeuroleptic medicationDA excretionNeurochemical studiesPRL valuesPeripheral indicesExcretion rateAcid levelsHVAExcretionSignificant differences
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply